|
1
|
Scalise M and Jaakola VP: Membrane
proteins: New approaches to probes, technologies, and drug design.
SLAS Discov. 24:865–866. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Curnow P: Designing minimalist membrane
proteins. Biochem Soc Trans. 47:1233–1245. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pandey A, Shin K, Patterson RE, Liu XQ and
Rainey JK: Current strategies for protein production and
purification enabling membrane protein structural biology. Biochem
Cell Biol. 94:507–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmit K and Michiels C: TMEM proteins in
cancer: A review. Front Pharmacol. 9:13452018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marx S, Dal Maso T, Chen JW, Bury M,
Wouters J, Michiels C and Le Calvé B: Transmembrane (TMEM) protein
family members: Poorly characterized even if essential for the
metastatic process. Semin Cancer Biol. 60:96–106. 2020. View Article : Google Scholar
|
|
6
|
Akkafa F, Koyuncu İ, Temiz E, Dagli H,
Dïlmec F and Akbas H: miRNA-mediated apoptosis activation through
TMEM 48 inhibition in A549 cell line. Biochem Biophys Res Commun.
503:323–329. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun Z, Zhao H, Yang S, Liu R, Yi L, Gao J,
Liu S, Chen Y and Zhang Z: Edaravone Dexborneol protects against
blood-brain barrier disruption following cerebral
ischemia/reperfusion by upregulating pericyte coverage via
vitronectin-integrin and PDGFB/PDGFR-β signaling. Free Radic Biol
Med. 225:758–766. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sabbah DA, Hajjo R and Sweidan K: Review
on epidermal growth factor receptor (EGFR) structure, signaling
pathways, interactions, and recent updates of EGFR inhibitors. Curr
Top Med Chem. 20:815–834. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Krook MA, Reeser JW, Ernst G, Barker H,
Wilberding M, Li G, Chen HZ and Roychowdhury S: Fibroblast growth
factor receptors in cancer: Genetic alterations, diagnostics,
therapeutic targets and mechanisms of resistance. Br J Cancer.
124:880–892. 2021. View Article : Google Scholar :
|
|
10
|
Rodrigues Toledo C, Tantawy AA, Lima
Fuscaldi L, Malavolta L and de Aguiar Ferreira C: EGFR- and
integrin α(V)β(3)-targeting peptides as potential
radiometal-labeled radiopharmaceuticals for cancer theranostics.
Int J Mol Sci. 25:85532024. View Article : Google Scholar
|
|
11
|
Chiaranunt P, Ferrara JL and Byersdorfer
CA: Rethinking the paradigm: How comparative studies on fatty acid
oxidation inform our understanding of T cell metabolism. Mol
Immunol. 68C:564–574. 2015. View Article : Google Scholar
|
|
12
|
Mohan CD, Rangappa KS and Sethi G:
Transmembrane protein 25 abrogates monomeric EGFR-driven STAT3
activation in triple-negative breast cancer. MedComm (2020).
5:e4922024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li S, Yue M, Xu H, Zhang X, Mao T, Quan M,
Ma J, Wang Y, Ge W, Wang Y, et al: Chemotherapeutic drugs-induced
pyroptosis mediated by gasdermin E promotes the progression and
chemoresistance of pancreatic cancer. Cancer Lett. 564:2162062023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee W, Song G and Bae H: Review of
synergistic anticancer effects of natural compounds combined with
conventional therapeutics against chemoresistance and progression
of pancreatic cancer. Mol Cell Toxicol. 21:455–471. 2025.
View Article : Google Scholar
|
|
15
|
Sato A, Takagi K, Yoshida M,
Yamaguchi-Tanaka M, Sagehashi M, Miki Y, Miyashita M and Suzuki T:
Discoidin domain receptor 2 contributes to breast cancer
progression and chemoresistance by interacting with collagen type
I. Cancers. 16:42852024. View Article : Google Scholar :
|
|
16
|
Hegde RS and Keenan RJ: The mechanisms of
integral membrane protein biogenesis. Nat Rev Mol Cell Biol.
23:107–124. 2022. View Article : Google Scholar
|
|
17
|
Li F, Egea PF, Vecchio AJ, Asial I, Gupta
M, Paulino J, Bajaj R, Dickinson MS, Ferguson-Miller S, Monk BC and
Stroud RM: Highlighting membrane protein structure and function: A
celebration of the Protein Data Bank. J Biol Chem. 296:1005572021.
View Article : Google Scholar
|
|
18
|
Tao X, Zhao C and MacKinnon R: Membrane
protein isolation and structure determination in cell-derived
membrane vesicles. Proc Natl Acad Sci USA. 120:e23023251202023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vénien-Bryan C and Fernandes CAH: Overview
of membrane protein sample preparation for single-particle
cryo-electron microscopy analysis. Int J Mol Sci. 24:147852023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Thonghin N, Kargas V, Clews J and Ford RC:
Cryo-electron microscopy of membrane proteins. Methods.
147:176–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gong J, Chen Y, Pu F, Sun P, He F, Zhang
L, Li Y, Ma Z and Wang H: Understanding membrane protein drug
targets in computational perspective. Curr Drug Targets.
20:551–564. 2019. View Article : Google Scholar
|
|
22
|
Gulezian E, Crivello C, Bednenko J, Zafra
C, Zhang Y, Colussi P and Hussain S: Membrane protein production
and formulation for drug discovery. Trends Pharmacol Sci.
42:657–674. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dodd RB, Wilkinson T and Schofield DJ:
Therapeutic monoclonal antibodies to complex membrane protein
targets: Antigen generation and antibody discovery strategies.
BioDrugs. 32:339–355. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao S, Xu T, Wang W, Li J, Shan Y, Wang Y
and Tan H: Polysaccharides from Anemarrhena asphodeloides Bge, the
extraction, purification, structure characterization, biological
activities and application of a traditional herbal medicine. Int J
Biol Macromol. 311:1434972025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao S, Wang W, Li J, Wang Y, Shan Y and
Tan H: Unveiling polysaccharides of Houttuynia cordata thunb:
Extraction, purification, structure, bioactivities, and
structure-activity relationships. Phytomedicine. 138:1564362025.
View Article : Google Scholar
|
|
26
|
Gao S, Li J, Wang W, Wang Y, Shan Y and
Tan H: Rabdosia rubescens (Hemsl.) H. Hara: A potent anti-tumor
herbal remedy - Botany, phytochemistry, and clinical applications
and insights. J Ethnopharmacol. 340:1192002025. View Article : Google Scholar
|
|
27
|
Chu XP and Xiong ZG: Acid-sensing ion
channels in pathological conditions. Adv Exp Med Biol. 961:419–431.
2013. View Article : Google Scholar :
|
|
28
|
Nandi PR: Pain in neurological conditions.
Curr Opin Support Palliat Care. 6:194–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jones F, Gamper N and Gao H: Kv7 channels
and excitability disorders. Handb Exp Pharmacol. 267:185–230. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang X, Liu Y, Xue C, Hu Y, Zhao Y, Cai K,
Li M and Luo Z: A protein-based cGAS-STING nanoagonist enhances T
cell-mediated anti-tumor immune responses. Nat Commun. 13:56852022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang SP, Chen FY, Dong LX, Zhang YQ, Chen
HY, Qiao K and Wang KJ: A novel innexin2 forming membrane
hemichannel exhibits immune responses and cell apoptosis in Scylla
paramamosain. Fish Shellfish Immunol. 47:485–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hauser AS, Attwood MM, Rask-Andersen M,
Schiöth HB and Gloriam DE: Trends in GPCR drug discovery: New
agents, targets and indications. Nat Rev Drug Discov. 16:829–842.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Snijder HJ and Hakulinen J: Membrane
protein production in E. coli for applications in drug discovery.
Adv Exp Med Biol. 896:59–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kandasamy P, Gyimesi G, Kanai Y and
Hediger MA: Amino acid transporters revisited: New views in health
and disease. Trends Biochem Sci. 43:752–789. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kampen KR: Membrane proteins: the key
players of a cancer cell. J Membr Biol. 242:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Singh V, Kaur R, Kumari P, Pasricha C and
Singh R: ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and
cardiovascular disorders. Clin Chim Acta. 548:1174872023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pliego-Arreaga R, Cervantes-Montelongo JA,
Silva-Martínez GA, Tristán-Flores FE, Pantoja-Hernández MA and
Maldonado-Coronado JR: Joint hypermobility syndrome and membrane
proteins: A comprehensive review. Biomolecules. 14:4722024.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guan Q, Bhowmick B, Upadhyay A and Han Q:
Structure and functions of bacterial outer membrane protein A, a
potential therapeutic target for bacterial infection. Curr Top Med
Chem. 21:1129–1138. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang H and Lee CJ: Transmembrane proteins
with unknown function (TMEMs) as ion channels: Electrophysiological
properties, structure, and pathophysiological roles. Exp Mol Med.
56:850–860. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li L and Li J: Dimerization of
transmembrane proteins in cancer immunotherapy. Membranes.
13:3932023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wesoly J, Pstrąg N, Derylo K,
Michalec-Wawiórka B, Derebecka N, Nowicka H, Kajdasz A, Kluzek K,
Srebniak M, Tchórzewski M, et al: Structural, topological, and
functional characterization of transmembrane proteins TMEM213, 207,
116, 72 and 30B provides a potential link to ccRCC etiology. Am J
Cancer Res. 13:1863–1883. 2023.PubMed/NCBI
|
|
42
|
Nieto Gutierrez A and McDonald PH: GPCRs:
Emerging anti-cancer drug targets. Cell Signal. 41:65–74. 2018.
View Article : Google Scholar
|
|
43
|
Dorsam RT and Gutkind JS:
G-protein-coupled receptors and cancer. Nat Rev Cancer. 7:79–94.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu X, Luo C, Wu J, Deng Y, Mu X, Zhang T,
Yang X, Liu Q, Li Z, Tang S, et al: Ion channels and transporters
regulate nutrient absorption in health and disease. J Cell Mol Med.
27:2631–2642. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Talukdar S, Emdad L, Das SK and Fisher PB:
EGFR: An essential receptor tyrosine kinase-regulator of cancer
stem cells. Adv Cancer Res. 147:161–188. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu Q, Huang J, Yan W, Liu Z, Liu S and
Fang W: FGFR families: Biological functions and therapeutic
interventions in tumors. MedComm (2020). 4:e3672023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Riordan R, Saxton A, McMillan PJ, Kow RL,
Liachko NF and Kraemer BC: TMEM106B C-terminal fragments aggregate
and drive neurodegenerative proteinopathy. bioRxiv [Preprint]:
2024.06.11.598478. 2024.
|
|
48
|
Eber E, Trawinska-Bartnicka M, Sands D,
Bellon G, Mellies U, Bolbás K, Quattrucci S, Mazurek H, Widmann R,
Schoergenhofer C, et al: Aerosolized lancovutide in adolescents
(≥12 years) and adults with cystic fibrosis-a randomized trial. J
Cyst Fibros. 20:61–67. 2021. View Article : Google Scholar
|
|
49
|
Vovdenko S, Morozov A, Ali S, Kogan E and
Bezrukov E: Role of monocarboxylate transporters and glucose
transporters in prostate cancer. Urologia. 90:491–498. 2023.
View Article : Google Scholar
|
|
50
|
Pérez-Herrero E and Fernández-Medarde A:
Advanced targeted therapies in cancer: Drug nanocarriers, the
future of chemotherapy. Eur J Pharm Biopharm. 93:52–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Perneel J, Neumann M, Heeman B, Cheung S,
Van den Broeck M, Wynants S, Baker M, Vicente CT, Faura J,
Rademakers R and Mackenzie IRA: Accumulation of TMEM106B C-terminal
fragments in neurodegenerative disease and aging. Acta Neuropathol.
145:285–302. 2023. View Article : Google Scholar
|
|
52
|
Granholm AE, Englund E, Gilmore A, Head E,
Yong WH, Perez SE, Guzman SJ, Hamlett ED and Mufson EJ:
Neuropathological findings in Down syndrome, Alzheimer's disease
and control patients with and without SARS-COV-2: Preliminary
findings. Acta Neuropathol. 147:922024. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tran Q, Park J, Lee H, Hong Y, Hong S,
Park S, Park J and Kim SH: TMEM39A and human diseases: A brief
review. Toxicol Res. 33:205–209. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Jankauskas SS, Varzideh F, Kansakar U, Al
Tibi G, Densu Agyapong E, Gambardella J and Santulli G: Insights
into molecular and cellular functions of the Golgi
calcium/manganese-proton antiporter TMEM165. J Biol Chem.
300:1075672024. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Dutta D, Kanca O, Shridharan RV,
Marcogliese PC, Steger B, Morimoto M, Frost FG, Macnamara E;
Undiagnosed Diseases Network; Wangler MF, et al: Loss of the
endoplasmic reticulum protein Tmem208 affects cell polarity,
development, and viability. Proc Natl Acad Sci USA.
121:e23225821212024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hayez A, Roegiers E, Malaisse J, Balau B,
Sterpin C, Achouri Y, De Rouvroit CL, Poumay Y, Michiels C and De
Backer O: TMEM45A is dispensable for epidermal morphogenesis,
keratinization and barrier formation. PLoS One. 11:e01470692016.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gallos G, Remy KE, Danielsson J, Funayama
H, Fu XW, Chang HY, Yim P, Xu D and Emala CW Sr: Functional
expression of the TMEM16 family of calcium-activated chloride
channels in airway smooth muscle. Am J Physiol Lung Cell Mol
Physiol. 305:L625–L634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Dulary E, Potelle S, Legrand D and
Foulquier F: TMEM165 deficiencies in congenital disorders of
glycosylation type II (CDG-II): Clues and evidences for roles of
the protein in Golgi functions and ion homeostasis. Tissue Cell.
49A:150–156. 2017. View Article : Google Scholar
|
|
59
|
Dodeller F, Gottar M, Huesken D, Iourgenko
V and Cenni B: The lysosomal transmembrane protein 9B regulates the
activity of inflammatory signaling pathways. J Biol Chem.
283:21487–21494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Herrera-Quiterio GA and
Encarnación-Guevara S: The transmembrane proteins (TMEM) and their
role in cell proliferation, migration, invasion, and
epithelial-mesenchymal transition in cancer. Front Oncol.
13:12447402023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jeon M, Yoo S, Park S, Choi Y, An J, Noh
YR and Kim I: Over-expression of transmembrane protein 158 predicts
aggressive tumor behavior and poor prognosis in lung cancer.
Anticancer Res. 44:4885–4893. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pedemonte N and Galietta LJ: Structure and
function of TMEM16 proteins (anoctamins). Physiol Rev. 94:419–459.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shi L, Wang X, Guo S, Gou H, Shang H,
Jiang X, Wei C, Wang J, Li C, Wang L, et al: TMEM65 promotes
gastric tumorigenesis by targeting YWHAZ to activate PI3K-Akt-mTOR
pathway and is a therapeutic target. Oncogene. 43:931–943. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Shepard HM, Phillips GL, D Thanos C and
Feldmann M: Developments in therapy with monoclonal antibodies and
related proteins. Clin Med. 17:220–232. 2017. View Article : Google Scholar
|
|
65
|
Posner J, Barrington P, Brier T and
Datta-Mannan A: Monoclonal antibodies: Past, present and future.
Handb Exp Pharmacol. 260:81–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shaikh MH, Barrett JW, Khan MI, Kim HAJ,
Zeng PYF, Mymryk JS and Nichols AC: Chromosome 3p loss in the
progression and prognosis of head and neck cancer. Oral Oncol.
109:1049442020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhou X, Popescu NC, Klein G and Imreh S:
The interferon-alpha responsive gene TMEM7 suppresses cell
proliferation and is downregulated in human hepatocellular
carcinoma. Cancer Genet Cytogenet. 177:6–15. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kholodnyuk ID, Kozireva S, Kost-Alimova M,
Kashuba V, Klein G and Imreh S: Down regulation of 3p genes, LTF,
SLC38A3 and DRR1, upon growth of human chromosome 3-mouse
fibrosarcoma hybrids in severe combined immunodeficiency mice. Int
J Cancer. 119:99–107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kiss H, Darai E, Kiss C, Kost-Alimova M,
Klein G, Dumanski JP and Imreh S: Comparative human/murine sequence
analysis of the common eliminated region 1 from human 3p21.3. Mamm
Genome. 13:646–655. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hrašovec S, Hauptman N, Glavač D, Jelenc F
and Ravnik-Glavač M: TMEM25 is a candidate biomarker methylated and
down-regulated in colorectal cancer. Dis Markers. 34:93–104. 2013.
View Article : Google Scholar
|
|
71
|
Bi J, Wu Z, Zhang X, Zeng T, Dai W, Qiu N,
Xu M, Qiao Y, Ke L, Zhao J, et al: TMEM25 inhibits monomeric
EGFR-mediated STAT3 activation in basal state to suppress
triple-negative breast cancer progression. Nat Commun. 14:23422023.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Doolan P, Clynes M, Kennedy S, Mehta JP,
Germano S, Ehrhardt C, Crown J and O'Driscoll L: TMEM25, REPS2 and
Meis 1: Favourable prognostic and predictive biomarkers for breast
cancer. Tumour Biol. 30:200–209. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xi P, Zhang Z, Liu Y, Nie Y, Gong B, Liu
J, Huang H, Liu Z, Sun T and Xie W: Multidimensional comprehensive
and integrated analysis of the potential function of TMEM25 in
renal clear cell carcinoma with low expression status. Aging
(Albany NY). 16:367–388. 2024.PubMed/NCBI
|
|
74
|
Cai M, Ni WJ, Wang YH, Wang JJ and Zhou H:
Targeting TMEM88 as an attractive therapeutic strategy in malignant
tumors. Front Oncol. 12:9063722022. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ge YX, Wang CH, Hu FY, Pan LX, Min J, Niu
KY, Zhang L, Li J and Xu T: New advances of TMEM88 in cancer
initiation and progression, with special emphasis on Wnt signaling
pathway. J Cell Physiol. 233:79–87. 2018. View Article : Google Scholar
|
|
76
|
Li LY, Yang CC, Li SW, Liu YM, Li HD, Hu
S, Zhou H, Wang JL, Shen H, Meng XM, et al: TMEM88 modulates the
secretion of inflammatory factors by regulating YAP signaling
pathway in alcoholic liver disease. Inflamm Res. 69:789–800. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Geng Q, Chen X and Chen N: Transmembrane
protein 88 exerts a tumor-inhibitory role in thyroid cancer through
restriction of Wnt/β-catenin signaling. Exp Cell Res.
395:1121932020. View Article : Google Scholar
|
|
78
|
Nusse R and Clevers H: Wnt/β-Catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Zhao X, Li G, Chong T, Xue L, Luo Q, Tang
X, Zhai X, Chen J and Zhang X: TMEM88 exhibits an antiproliferative
and anti-invasive effect in bladder cancer by downregulating
Wnt/β-catenin signaling. J Biochem Mol Toxicol. 35:e228352021.
View Article : Google Scholar
|
|
80
|
Zhang X, Yu X, Jiang G, Miao Y, Wang L,
Zhang Y, Liu Y, Fan C, Lin X, Dong Q, et al: Cytosolic TMEM88
promotes invasion and metastasis in lung cancer cells by binding
DVLS. Cancer Res. 75:4527–4537. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ma R, Feng N, Yu X, Lin H, Zhang X, Shi O,
Zhang H, Zhang S, Li L, Zheng M, et al: Promoter methylation of
Wnt/β-Catenin signal inhibitor TMEM88 is associated with
unfavorable prognosis of non-small cell lung cancer. Cancer Biol
Med. 14:377–386. 2017. View Article : Google Scholar
|
|
82
|
Yu X, Zhang X, Zhang Y, Jiang G, Mao X and
Jin F: Cytosolic TMEM88 promotes triple-negative breast cancer by
interacting with Dvl. Oncotarget. 6:25034–25045. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Mao D, Yan F, Zhang X and Gao G: TMEM106A
inhibits enveloped virus release from cell surface. iScience.
25:1038432022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Xu D, Qu L, Hu J, Li G, Lv P, Ma D, Guo M
and Chen Y: Transmembrane protein 106A is silenced by promoter
region hypermethylation and suppresses gastric cancer growth by
inducing apoptosis. J Cell Mol Med. 18:1655–1666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Choi B, Han TS, Min J, Hur K, Lee SM, Lee
HJ, Kim YJ and Yang HK: MAL and TMEM220 are novel DNA methylation
markers in human gastric cancer. Biomarkers. 22:35–44. 2017.
View Article : Google Scholar
|
|
86
|
Wu C, Xu J, Wang H, Zhang J, Zhong J, Zou
X, Chen Y, Yang G, Zhong Y, Lai D, et al: TMEM106a is a novel tumor
suppressor in human renal cancer. Kidney Blood Press Res.
42:853–864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Shi S, Wang B, Wan J, Song L, Zhu G, Du J,
Ye L, Zhao Q, Cai J, Chen Q, et al: TMEM106A transcriptionally
regulated by promoter methylation is involved in invasion and
metastasis of hepatocellular carcinoma. Acta Biochim Biophys Sin.
54:1008–1020. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Liu J and Zhu H: TMEM106A inhibits cell
proliferation, migration, and induces apoptosis of lung cancer
cells. J Cell Biochem. 120:7825–7833. 2019. View Article : Google Scholar
|
|
89
|
Hou J, Niu Y, Yan J, Tian J, Yu W, Zhang
G, Li T and Wang Z: Non-invasive diagnosis for urothelial carcinoma
using a dual-target DNA methylation biomarker panel. Clin Chim
Acta. 569:1201642025. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Guo X, Zeng S, Ji X, Meng X, Lei N, Yang H
and Mu X: Type I Interferon-induced TMEM106A blocks attachment of
EV-A71 virus by interacting with the membrane protein SCARB2. Front
Immunol. 13:8178352022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang X, Feng T, Zhou X, Sullivan PM, Hu
F, Lou Y, Yu J, Feng J, Liu H and Chen Y: Inactivation of TMEM106A
promotes lipopolysaccharide-induced inflammation via the MAPK and
NF-κB signaling pathways in macrophages. Clin Exp Immunol.
203:125–136. 2021. View Article : Google Scholar
|
|
92
|
Sun Z and Hornung V: cGAS-STING signaling.
Curr Biol. 32:R730–R734. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Chen C and Xu P: Cellular functions of
cGAS-STING signaling. Trends Cell Biol. 33:630–648. 2023.
View Article : Google Scholar
|
|
94
|
Luo X, Li H, Ma L, Zhou J, Guo X, Woo SL,
Pei Y, Knight LR, Deveau M, Chen Y, et al: Expression of STING is
increased in liver tissues from patients with NAFLD and promotes
macrophage-mediated hepatic inflammation and fibrosis in mice.
Gastroenterology. 155:1971–1984.e4. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Yu Y, Liu Y, An W, Song J, Zhang Y and
Zhao X: STING-mediated inflammation in Kupffer cells contributes to
progression of nonalcoholic steatohepatitis. J Clin Invest.
129:546–555. 2019. View Article : Google Scholar :
|
|
96
|
Chin KH, Tu ZL, Su YC, Yu YJ, Chen HC, Lo
YC, Chen CP, Barber GN, Chuah ML, Liang ZX and Chou SH: Novel
c-di-GMP recognition modes of the mouse innate immune adaptor
protein STING. Acta Crystallogr D Biol Crystallogr. 69:352–366.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Liu D, Liang S, Ma K, Meng QF, Li X, Wei
J, Zhou M, Yun K, Pan Y, Rao L, et al: Tumor
microenvironment-responsive nanoparticles amplifying STING
signaling pathway for cancer immunotherapy. Adv Mater.
36:e23048452024. View Article : Google Scholar
|
|
98
|
Garland KM, Sheehy TL and Wilson JT:
Chemical and biomolecular strategies for STING pathway activation
in cancer immunotherapy. Chem Rev. 122:5977–6039. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Liang S, Ma H, Liu Y, Hai L, Tian Y, Sun Y
and Wang Z: Nano-immunomodulator amplifies STING activation in
tumor-associated macrophages for cancer immunotherapy. J Control
Release. 383:1138462025. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Deng A, Fan R, Hai Y, Zhuang J, Zhang B,
Lu X, Wang W, Luo L, Bai G, Liang L, et al: A STING agonist prodrug
reprograms tumor-associated macrophage to boost colorectal cancer
immunotherapy. Theranostics. 15:277–299. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Ishikawa T, Tamura E, Kasahara M, Uchida
H, Higuchi M, Kobayashi H, Shimizu H, Ogawa E, Yotani N, Irie R, et
al: Severe liver disorder following liver transplantation in
STING-Associated vasculopathy with onset in infancy. J Clin
Immunol. 41:967–974. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Song H, Chen L, Pan X, Shen Y, Ye M, Wang
G, Cui C, Zhou Q, Tseng Y, Gong Z, et al: Targeting tumor
monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing
STING agonist therapy. Cancer Cell. 43:503–518.e0. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Li S, Mirlekar B, Johnson BM, Brickey WJ,
Wrobel JA, Yang N, Song D, Entwistle S, Tan X, Deng M, et al:
STING-induced regulatory B cells compromise NK function in cancer
immunity. Nature. 610:373–380. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Larabi A, Barnich N and Nguyen HTT: New
insights into the interplay between autophagy, gut microbiota and
inflammatory responses in IBD. Autophagy. 16:38–51. 2020.
View Article : Google Scholar :
|
|
105
|
Bu Y, Liu F, Jia QA and Yu SN: Decreased
expression of TMEM173 predicts poor prognosis in patients with
hepatocellular carcinoma. PLoS One. 11:e01656812016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang J, Li S, Wang M, Wang X, Chen S, Sun
Z, Ren X, Huang G, Sumer BD, Yan N, et al: STING licensing of type
I dendritic cells potentiates antitumor immunity. Sci Immunol.
9:eadj39452024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Lai P, Liu L, Bancaro N, Troiani M, Calì
B, Li Y, Chen J, Singh PK, Arzola RA, Attanasio G, et al:
Mitochondrial DNA released by senescent tumor cells enhances
PMN-MDSC-driven immunosuppression through the cGAS-STING pathway.
Immunity. 58:811–825.e7. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Zeng Q, Liu M, Wang Z, Zhou R and Ai K:
Enhancing radiotherapy-induced anti-tumor immunity via
nanoparticle-mediated STING agonist synergy. Mol Cancer.
24:1762025. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Riegman PH, Burgart LJ, Wang KK,
Wink-Godschalk JC, Dinjens WN, Siersema PD, Tilanus HW and van
Dekken H: Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in
Barrett's esophagus. Cancer Res. 62:1531–1533. 2002.PubMed/NCBI
|
|
110
|
Hill M, Russo S, Olivera D, Malcuori M,
Galliussi G and Segovia M: The intracellular cation channel
TMEM176B as a dual immunoregulator. Front Cell Dev Biol.
10:10384292022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang Y, Zhang Y, Herman JG, Linghu E and
Guo M: Epigenetic silencing of TMEM176A promotes esophageal
squamous cell cancer development. Oncotarget. 8:70035–70048. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gao D, Han Y, Yang Y, Herman JG, Linghu E,
Zhan Q, Fuks F, Lu ZJ and Guo M: Methylation of TMEM176A is an
independent prognostic marker and is involved in human colorectal
cancer development. Epigenetics. 12:575–583. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Liu Z, An H, Song P, Wang D, Li S, Chen K
and Pang Q: Potential targets of TMEM176A in the growth of
glioblastoma cells. Onco Targets Ther. 11:7763–7775. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Qian W, Xu CY, Hong W, Li ZM and Xu DG:
Transmembrane protein 176B promotes epithelial-mesenchymal
transition in colorectal cancer through inflammasome inhibition.
World J Gastrointest Oncol. 17:976732025. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Li J, Fang Z, Dal E, Zhang H, Yu K, Ma M,
Wang M, Sun R, Lu M, Wang H and Li Y: Transmembrane protein 176B
regulates amino acid metabolism through the PI3K-Akt-mTOR signaling
pathway and promotes gastric cancer progression. Cancer Cell Int.
24:952024. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Yan L, Song Z, Yi L, Tian C, Zhang R, Qin
X, Wang X, Ren S, Ma X, Wang X, et al: TMEM176B inhibits ovarian
cancer progression by regulating EMT via the Wnt/β-catenin
signaling pathway. J Transl Med. 23:3502025. View Article : Google Scholar
|
|
117
|
Condamine T, Le Texier L, Howie D, Lavault
A, Hill M, Halary F, Cobbold S, Waldmann H, Cuturi MC and
Chiffoleau E: Tmem176B and Tmem176A are associated with the
immature state of dendritic cells. J Leukoc Biol. 88:507–515. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Segovia M, Louvet C, Charnet P, Savina A,
Tilly G, Gautreau L, Carretero-Iglesia L, Beriou G, Cebrian I, Cens
T, et al: Autologous dendritic cells prolong allograft survival
through Tmem176b-dependent antigen cross-presentation. Am J
Transplant. 14:1021–1031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Segovia M, Russo S, Jeldres M, Mahmoud YD,
Perez V, Duhalde M, Charnet P, Rousset M, Victoria S, Veigas F, et
al: Targeting TMEM176B enhances antitumor immunity and augments the
efficacy of immune checkpoint blockers by unleashing inflammasome
activation. Cancer Cell. 35:767–781.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Victoria S, Castro A, Pittini A, Olivera
D, Russo S, Cebrian I, Mombru AW, Osinaga E, Pardo H, Segovia M and
Hill M: Formulating a TMEM176B blocker in chitosan nanoparticles
uncouples its paradoxical roles in innate and adaptive antitumoral
immunity. Int J Biol Macromol. 279:1353272024. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Jiang L, Yang Y, Liu F, Ma M, Gao J, Sun
L, Chen Y, Shen Z and Wu D: A potential diagnostic and prognostic
biomarker TMEM176B and its relationship with immune infiltration in
skin cutaneous melanoma. Front Cell Dev Biol. 10:8599582022.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Jing L, An Y, Cai T, Xiang J, Li B, Guo J,
Ma X, Wei L, Tian Y, Cheng X, et al: A subpopulation of CD146(+)
macrophages enhances antitumor immunity by activating the NLRP3
inflammasome. Cell Mol Immunol. 20:908–923. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Picotto G, Morse LR, Nguyen N, Saltzman J
and Battaglino R: TMEM176A and TMEM176B are candidate regulators of
inhibition of dendritic cell maturation and function after chronic
spinal cord injury. J Neurotrauma. 37:528–533. 2020. View Article : Google Scholar :
|
|
124
|
Cuajungco MP, Podevin W, Valluri VK, Bui
Q, Nguyen VH and Taylor K: Abnormal accumulation of human
transmembrane (TMEM)-176A and 176B proteins is associated with
cancer pathology. Acta Histochem. 114:705–712. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Li H, Zhang M, Linghu E, Zhou F, Herman
JG, Hu L and Guo M: Epigenetic silencing of TMEM176A activates ERK
signaling in human hepatocellular carcinoma. Clin Epigenetics.
10:1372018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Al-Hosni R, Ilkan Z, Agostinelli E and
Tammaro P: The pharmacology of the TMEM16A channel: therapeutic
opportunities. Trends Pharmacol Sci. 43:712–725. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Okuyama K and Yanamoto S: TMEM16A as a
potential treatment target for head and neck cancer. J Exp Clin
Cancer Res. 41:1962022. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Bill A, Gutierrez A, Kulkarni S, Kemp C,
Bonenfant D, Voshol H, Duvvuri U and Gaither LA: ANO1/TMEM16A
interacts with EGFR and correlates with sensitivity to
EGFR-targeting therapy in head and neck cancer. Oncotarget.
6:9173–9188. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Wang F, Zhang Y, Gao M and Zeng X: TMEM16A
inhibits renal tubulointerstitial fibrosis via Wnt/β-catenin
signaling during hypertension nephropathy. Cell Signal.
117:1110882024. View Article : Google Scholar
|
|
130
|
Yan Y, Ding X, Han C, Gao J, Liu Z, Liu Y
and Wang K: Involvement of TMEM16A/ANO1 upregulation in the
oncogenesis of colorectal cancer. Biochim Biophys Acta Mol Basis
Dis. 1868:1663702022. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li H, Yu Z, Wang H, Wang N, Sun X, Yang S,
Hua X and Liu Z: Role of ANO1 in tumors and tumor immunity. J
Cancer Res Clin Oncol. 148:2045–2068. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Filippou A, Pehkonen H, Karhemo PR,
Väänänen J, Nieminen AI, Klefström J, Grénman R, Mäkitie AA,
Joensuu H and Monni O: ANO1 expression orchestrates
p27Kip1/MCL1-mediated signaling in head and neck squamous cell
carcinoma. Cancers. 13:11702021. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Shiwarski DJ, Shao C, Bill A, Kim J, Xiao
D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, et al: To
'grow' or 'go': TMEM16A expression as a switch between tumor growth
and metastasis in SCCHN. Clin Cancer Res. 20:4673–4688. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Godse NR, Khan N, Yochum ZA, Gomez-Casal
R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns
TF and Duvvuri U: TMEM16A/ANO1 inhibits apoptosis via
downregulation of bim expression. Clin Cancer Res. 23:7324–7332.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Ayoub C, Wasylyk C, Li Y, Thomas E, Marisa
L, Robé A, Roux M, Abecassis J, de Reyniès A and Wasylyk B: ANO1
amplification and expression in HNSCC with a high propensity for
future distant metastasis and its functions in HNSCC cell lines. Br
J Cancer. 103:715–726. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Dixit R, Kemp C, Kulich S, Seethala R,
Chiosea S, Ling S, Ha PK and Duvvuri U: TMEM16A/ANO1 is
differentially expressed in HPV-negative versus HPV-positive head
and neck squamous cell carcinoma through promoter methylation. Sci
Rep. 5:166572015. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Liu F, Cao QH, Lu DJ, Luo B, Lu XF, Luo RC
and Wang XG: TMEM16A overexpression contributes to tumor invasion
and poor prognosis of human gastric cancer through TGF-β signaling.
Oncotarget. 6:11585–11599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Britschgi A, Bill A, Brinkhaus H, Rothwell
C, Clay I, Duss S, Rebhan M, Raman P, Guy CT, Wetzel K, et al:
Calcium-activated chloride channel ANO1 promotes breast cancer
progression by activating EGFR and CAMK signaling. Proc Natl Acad
Sci USA. 110:E1026–E1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Bae JS, Park JY, Park SH, Ha SH, An AR,
Noh SJ, Kwon KS, Jung SH, Park HS, Kang MJ and Jang KY: Expression
of ANO1/DOG1 is associated with shorter survival and progression of
breast carcinomas. Oncotarget. 9:607–621. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Rhodes A, Jasani B, Balaton AJ, Barnes DM
and Miller KD: Frequency of oestrogen and progesterone receptor
positivity by immunohistochemical analysis in 7016 breast
carcinomas: correlation with patient age, assay sensitivity,
threshold value, and mammographic screening. J Clin Pathol.
53:688–696. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Meng Y, Liu Z, Zhai C, Di T, Zhang L,
Zhang L, Xie X, Lin Y, Wang N, Zhao J, et al: Paeonol inhibits the
development of 1-chloro-2,4-dinitrobenzene-induced atopic
dermatitis via mast and T cells in BALB/c mice. Mol Med Rep.
19:3217–3229. 2019.PubMed/NCBI
|
|
142
|
Sui Y, Sun M, Wu F, Yang L, Di W, Zhang G,
Zhong L, Ma Z, Zheng J, Fang X and Ma T: Inhibition of TMEM16A
expression suppresses growth and invasion in human colorectal
cancer cells. PLoS One. 9:e1154432014. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li H, Yang Q, Huo S, Du Z, Wu F, Zhao H,
Chen S, Yang L, Ma Z and Sui Y: Expression of TMEM16A in colorectal
cancer and its correlation with clinical and pathological
parameters. Front Oncol. 11:6522622021. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Liu W, Lu M, Liu B, Huang Y and Wang K:
Inhibition of Ca(2+)-activated Cl(-) channel ANO1/TMEM16A
expression suppresses tumor growth and invasiveness in human
prostate carcinoma. Cancer Lett. 326:41–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Song Y, Gao J, Guan L, Chen X, Gao J and
Wang K: Inhibition of ANO1/TMEM16A induces apoptosis in human
prostate carcinoma cells by activating TNF-α signaling. Cell Death
Dis. 9:7032018. View Article : Google Scholar
|
|
146
|
Jeon D, Jo M, Lee Y, Park SH, Phan HTL,
Nam JH and Namkung W: Inhibition of ANO1 by cis- and
trans-resveratrol and their anticancer activity in human prostate
cancer PC-3 cells. Int J Mol Sci. 24:11862023. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Seo Y, Ryu K, Park J, Jeon DK, Jo S, Lee
HK and Namkung W: Inhibition of ANO1 by luteolin and its
cytotoxicity in human prostate cancer PC-3 cells. PLoS One.
12:e01749352017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Liu Z, Zhang S, Hou F, Zhang C, Gao J and
Wang K: Inhibition of Ca(2+) -activated chloride channel ANO1
suppresses ovarian cancer through inactivating PI3K/Akt signaling.
Int J Cancer. 144:2215–2226. 2019. View Article : Google Scholar
|
|
149
|
Bai X, Cheng Y, Wan H, Li S, Kang X and
Guo S: Natural compound allicin containing thiosulfinate moieties
as transmembrane protein 16A (TMEM16A) Ion channel inhibitor for
food adjuvant therapy of lung cancer. J Agric Food Chem.
71:535–545. 2023. View Article : Google Scholar
|
|
150
|
Seo Y, Park J, Kim M, Lee HK, Kim JH,
Jeong JH and Namkung W: Inhibition of ANO1/TMEM16A chloride channel
by idebenone and its cytotoxicity to cancer cell lines. PLoS One.
10:e01336562015. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yin L, Menon R, Gupta R, Vaught L,
Okunieff P and Vidyasagar S: Glucose enhances rotavirus
enterotoxin-induced intestinal chloride secretion. Pflugers Arch.
469:1093–1105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Hayez A, Malaisse J, Roegiers E, Reynier
M, Renard C, Haftek M, Geenen V, Serre G, Simon M, de Rouvroit CL,
et al: High TMEM45A expression is correlated to epidermal
keratinization. Exp Dermatol. 23:339–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Sun W, Qiu G, Zou Y, Cai Z, Wang P, Lin X,
Huang J, Jiang L, Ding X and Hu G: Knockdown of TMEM45A inhibits
the proliferation, migration and invasion of glioma cells. Int J
Clin Exp Pathol. 8:12657–12667. 2015.
|
|
154
|
Guo J, Chen L, Luo N, Yang W, Qu X and
Cheng Z: Inhibition of TMEM45A suppresses proliferation, induces
cell cycle arrest and reduces cell invasion in human ovarian cancer
cells. Oncol Rep. 33:3124–3130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Manawapat-Klopfer A, Thomsen LT, Martus P,
Munk C, Russ R, Gmuender H, Frederiksen K, Haedicke-Jarboui J,
Stubenrauch F, Kjaer SK and Iftner T: TMEM45A, SERPINB5 and
p16INK4A transcript levels are predictive for development of
high-grade cervical lesions. Am J Cancer Res. 6:1524–1536.
2016.PubMed/NCBI
|
|
156
|
Liu Y, Liu L and Mou ZX: TMEM45A affects
proliferation, apoptosis, epithelial-mesenchymal transition,
migration, invasion and cisplatin resistance of HPV-Positive
cervical cancer cell lines. Biochem Genet. 60:173–190. 2022.
View Article : Google Scholar
|
|
157
|
Neuperger P, Balog J, Tiszlavicz L, Furák
J, Gémes N, Kotogány E, Szalontai K, Puskás LG and Szebeni GJ:
Analysis of the single-cell heterogeneity of adenocarcinoma cell
lines and the investigation of intratumor heterogeneity reveals the
expression of transmembrane protein 45A (TMEM45A) in lung
adenocarcinoma cancer patients. Cancers. 14:1442021. View Article : Google Scholar
|
|
158
|
Jiang H, Chen H, Wan P, Liang M and Chen
N: Upregulation of TMEM45A promoted the progression of clear cell
renal cell carcinoma in vitro. J Inflamm Res. 14:6421–6430. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Xie Q, Guo T, Deng H, Yu C and Fang C:
Pan-cancer analysis of TMEM45A and exploration of its prognostic
value and mechanism in gastric cancer. Cell Mol Biol. 70:218–229.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Chen C, Chen Z, Zhao J, Wen X, Yao H, Weng
Z, Xiong H, Zheng Z and Wu J: TMEM45A enhances palbociclib
resistance and cellular glycolysis by activating AKT/mTOR signaling
pathway in HR+ breast cancer. Cell Death Discov.
11:472025. View Article : Google Scholar
|
|
161
|
Flamant L, Roegiers E, Pierre M, Hayez A,
Sterpin C, De Backer O, Arnould T, Poumay Y and Michiels C: TMEM45A
is essential for hypoxia-induced chemoresistance in breast and
liver cancer cells. BMC Cancer. 12:3912012. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Zhu M, Jiang B, Yan D, Wang X, Ge H and
Sun Y: Knockdown of TMEM45A overcomes multidrug resistance and
epithelial-mesenchymal transition in human colorectal cancer cells
through inhibition of TGF-β signalling pathway. Clin Exp Pharmacol
Physiol. 47:503–516. 2020. View Article : Google Scholar
|
|
163
|
Okada N, Yamamoto T, Watanabe M, Yoshimura
Y, Obana E, Yamazaki N, Kawazoe K, Shinohara Y and Minakuchi K:
Identification of TMEM45B as a protein clearly showing thermal
aggregation in SDS-PAGE gels and dissection of its amino acid
sequence responsible for this aggregation. Protein Expr Purif.
77:118–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Hu R, Hu F, Xie X, Wang L, Li G, Qiao T,
Wang M and Xiao H: TMEM45B, up-regulated in human lung cancer,
enhances tumorigenicity of lung cancer cells. Tumour Biol.
37:12181–12191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhao LC, Shen BY, Deng XX, Chen H, Zhu ZG
and Peng CH: TMEM45B promotes proliferation, invasion and migration
and inhibits apoptosis in pancreatic cancer cells. Mol Biosyst.
12:1860–1870. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Shen K, Yu W, Yu Y, Liu X and Cui X:
Knockdown of TMEM45B inhibits cell proliferation and invasion in
gastric cancer. Biomed Pharmacother. 104:576–581. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Li Y, Guo W, Liu S, Zhang B, Yu BB, Yang
B, Kan SL and Feng SQ: Silencing transmembrane protein 45B
(TNEM45B) inhibits proliferation, invasion, and tumorigenesis in
osteosarcoma cells. Oncol Res. 25:1021–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Tanioku T, Nishibata M, Tokinaga Y, Konno
K, Watanabe M, Hemmi H, Fukuda-Ohta Y, Kaisho T, Furue H and
Kawamata T: Tmem45b is essential for inflammation- and tissue
injury-induced mechanical pain hypersensitivity. Proc Natl Acad Sci
USA. 119:e21219891192022. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Luo F, Yang K, Wang YZ and Lin D: TMEM45B
is a novel predictive biomarker for prostate cancer progression and
metastasis. Neoplasma. 65:815–821. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Stavru F, Hülsmann BB, Spang A, Hartmann
E, Cordes VC and Görlich D: NDC1: A crucial membrane-integral
nucleoporin of metazoan nuclear pore complexes. J Cell Biol.
173:509–519. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
D'Angelo MA and Hetzer MW: Structure,
dynamics and function of nuclear pore complexes. Trends Cell Biol.
18:456–466. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Mahipal A and Malafa M: Importins and
exportins as therapeutic targets in cancer. Pharmacol Ther.
164:135–143. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Qiao W, Han Y, Jin W, Tian M, Chen P, Min
J, Hu H, Xu B, Zhu W, Xiong L and Lin Q: Overexpression and
biological function of TMEM48 in non-small cell lung carcinoma.
Tumour Biol. 37:2575–2586. 2016. View Article : Google Scholar
|
|
174
|
Jiang XY, Wang L, Liu ZY, Song WX, Zhou M
and Xi L: TMEM48 promotes cell proliferation and invasion in
cervical cancer via activation of the Wnt/β-catenin pathway. J
Recept Signal Transduct Res. 41:371–377. 2021. View Article : Google Scholar
|
|
175
|
Nazli A, Safdar A, Saleem A, Akhtar M,
Brady LI, Schwartzentruber J and Tarnopolsky MA: A mutation in the
TMEM65 gene results in mitochondrial myopathy with severe
neurological manifestations. Eur J Hum Genet. 25:744–751. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Zhang B, Liu Q, Wen W, Gao H, Wei W, Tang
A, Qin B, Lyu H, Meng X, Li K, et al: The chromatin remodeler CHD6
promotes colorectal cancer development by regulating
TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling.
Cell Discov. 8:1302022. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Zhang YL, Huang MY, Yang SY, Cai JY, Zhao
Q, Zhang FL, Hu X, Shao ZM, Liao L, Cao AY and Li DQ:
MYC/TET3-regulated TMEM65 activates OXPHOS-SERPINB3 pathway to
promote progression and cisplatin resistance in triple-negative
breast cancer. Adv Sci. 12:e004212025. View Article : Google Scholar
|
|
178
|
Qian Z, Liang J, Huang R, Song W, Ying J,
Bi X, Zhao J, Shi Z, Liu W, Liu J, et al: HBV integrations
reshaping genomic structures promote hepatocellular carcinoma. Gut.
73:1169–1182. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Song X, Wang P, Feng R, Chetry M, Li E, Wu
X, Liu Z, Liao S and Lin J: Pan-cancer analysis of prognostic and
immune infiltrates for the TMEM65, especially for the breast
cancer. Evid Based Complement Alternat Med. 2023:93494942023.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Li X, Zhou J, Zhang W, You W, Wang J, Zhou
L, Liu L, Chen WW and Li H: Pan-cancer analysis identifies tumor
cell surface targets for CAR-T cell therapies and antibody drug
conjugates. Cancers. 14:56742022. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Li B, Huang MZ, Wang XQ, Tao BB, Zhong J,
Wang XH, Zhang WC and Li ST: TMEM140 is associated with the
prognosis of glioma by promoting cell viability and invasion. J
Hematol Oncol. 8:892015. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Shimizu N, Noda S, Katayama K, Ichikawa H,
Kodama H and Miyoshi H: Identification of genes potentially
involved in supporting hematopoietic stem cell activity of stromal
cell line MC3T3-G2/PA6. Int J Hematol. 87:239–245. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Guan Y, Guo L, Yang E, Liao Y, Liu L, Che
Y, Zhang Y, Wang L, Wang J and Li Q: HSV-1 nucleocapsid egress
mediated by UL31 in association with UL34 is impeded by cellular
transmembrane protein 140. Virology. 464-465:1–10. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Chen WC, Wang CY, Hung YH, Weng TY, Yen MC
and Lai MD: Systematic analysis of gene expression alterations and
clinical outcomes for long-chain acyl-coenzyme a synthetase family
in cancer. PLoS One. 11:e01556602016. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Refaat A, Owis M, Abdelhamed S, Saiki I
and Sakurai H: Retrospective screening of microarray data to
identify candidate IFN-inducible genes in a HTLV-1 transformed
model. Oncol Lett. 15:4753–4758. 2018.PubMed/NCBI
|
|
186
|
Baker Frost D, da Silveira W, Hazard ES,
Atanelishvili I, Wilson RC, Flume J, Day KL, Oates JC, Bogatkevich
GS, Feghali-Bostwick C, et al: Differential DNA methylation
landscape in skin fibroblasts from African Americans with systemic
sclerosis. Genes. 12:1292021. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Barradas M, Gonos ES, Zebedee Z, Kolettas
E, Petropoulou C, Delgado MD, León J, Hara E and Serrano M:
Identification of a candidate tumor-suppressor gene specifically
activated during Ras-induced senescence. Exp Cell Res. 273:127–137.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Li J, Wang X, Chen L, Zhang J, Zhang Y,
Ren X, Sun J, Fan X, Fan J, Li T, et al: TMEM158 promotes the
proliferation and migration of glioma cells via STAT3 signaling in
glioblastomas. Cancer Gene Ther. 29:1117–1129. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Zirn B, Samans B, Wittmann S, Pietsch T,
Leuschner I, Graf N and Gessler M: Target genes of the
WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer.
45:565–574. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Mohammed Ael S, Eguchi H, Wada S, Koyama
N, Shimizu M, Otani K, Ohtaki M, Tanimoto K, Hiyama K, Gaber MS and
Nishiyama M: TMEM158 and FBLP1 as novel marker genes of cisplatin
sensitivity in non-small cell lung cancer cells. Exp Lung Res.
38:463–474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Fu Y, Yao N, Ding D, Zhang X, Liu H, Ma L,
Shi W, Zhu C and Tang L: TMEM158 promotes pancreatic cancer
aggressiveness by activation of TGFβ1 and PI3K/AKT signaling
pathway. J Cell Physiol. 235:2761–2775. 2020. View Article : Google Scholar
|
|
192
|
Cui X, Lu J, Zhao C and Duan Y: Oncogenic
transmembrane protein 158 drives the PI3K/Akt signaling pathway to
accelerate gastric cancer cell growth. Braz J Med Biol Res.
56:e129432023. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Liu L, Zhang J, Li S, Yin L and Tai J:
Silencing of TMEM158 inhibits tumorigenesis and multidrug
resistance in colorectal cancer. Nutr Cancer. 72:662–671. 2020.
View Article : Google Scholar
|
|
194
|
Cheng Z, Guo J, Chen L, Luo N, Yang W and
Qu X: Overexpression of TMEM158 contributes to ovarian
carcinogenesis. J Exp Clin Cancer Res. 34:752015. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Zhu X, Liu T and Yin X: TMEM158, as plasma
cfRNA marker, promotes proliferation and doxorubicin resistance in
ovarian cancer. Pharmacogenomics J. 24:342024. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Tong J, Li H, Hu Y, Zhao Z and Li M:
TMEM158 regulates the canonical and non-canonical pathways of TGF-β
to mediate EMT in triple-negative breast cancer. J Cancer.
13:2694–2704. 2022. View Article : Google Scholar :
|
|
197
|
Li J, Hou H, Sun J, Ding Z, Xu Y and Li G:
Systematic pan-cancer analysis identifies transmembrane protein 158
as a potential therapeutic, prognostic and immunological biomarker.
Funct Integr Genomics. 23:1052023. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Huang J, Liu W, Zhang D, Lin B and Li B:
TMEM158 expression is negatively regulated by AR signaling and
associated with favorite survival outcomes in prostate cancers.
Front Oncol. 12:10234552022. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Jawinski P, Kirsten H, Sander C, Spada J,
Ulke C, Huang J, Burkhardt R, Scholz M, Hensch T and Hegerl U:
Human brain arousal in the resting state: A genome-wide association
study. Mol Psychiatry. 24:1599–1609. 2019. View Article : Google Scholar
|
|
200
|
Goodman JM: LDAF1 holds the key to seipin
function. Dev Cell. 51:544–545. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Shi J, Zhang Y, Chen Y, Guo T and Piao H:
Identification of TMEM159 as a biomarker of glioblastoma
progression based on immune characteristics. Biocell. 48:1241–1263.
2024. View Article : Google Scholar
|
|
202
|
Geng F, Cheng X, Wu X, Yoo JY, Cheng C,
Guo JY, Mo X, Ru P, Hurwitz B, Kim SH, et al: Inhibition of SOAT1
suppresses glioblastoma growth via blocking SREBP-1-mediated
lipogenesis. Clin Cancer Res. 22:5337–5348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Castro IG, Eisenberg-Bord M, Persiani E,
Rochford JJ, Schuldiner M and Bohnert M: Promethin is a conserved
seipin partner protein. Cells. 8:2682019. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Bohnert M: New friends for seipin -
Implications of seipin partner proteins in the life cycle of lipid
droplets. Semin Cell Dev Biol. 108:24–32. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Chartschenko E, Hugenroth M, Akhtar I,
Droste A, Kolkhof P, Bohnert M and Beller M: CG32803 is the fly
homolog of LDAF1 and influences lipid storage in vivo. Insect
Biochem Mol Biol. 133:1035122021. View Article : Google Scholar
|
|
206
|
Wagner V, Morton M, Dorayappan KDP,
Gonzalez A, Yu L, Sakaue T, Conrads T, Maxwell GL, Cosgrove C,
Backes F, et al: Circulating extracellular vesicles protein
expression for early prediction of platinum-resistance in
high-grade serous ovarian cancer. Oncogene. 44:1197–1203. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Rao J, Wu X, Zhou X, Deng R and Ma Y:
TMEM205 is an independent prognostic factor and is associated with
immune cell infiltrates in hepatocellular carcinoma. Front Genet.
11:5757762020. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Saini U, Smith BQ, Dorayappan KDP, Yoo JY,
Maxwell GL, Kaur B, Konishi I, O'Malley D, Cohn DE and Selvendiran
K: Targeting TMEM205 mediated drug resistance in ovarian clear cell
carcinoma using oncolytic virus. J Ovarian Res. 15:1302022.
View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Calo CA, Smith BQ, Dorayappan KDP, Saini
U, Lightfoot M, Wagner V, Kalaiyarasan D, Cosgrove C, Wang QE,
Maxwell GL, et al: Aberrant expression of TMEM205 signaling
promotes platinum resistance in ovarian cancer: An implication for
the antitumor potential of DAP compound. Gynecol Oncol.
164:136–145. 2022. View Article : Google Scholar
|
|
210
|
Sen T, Rodriguez BL, Chen L, Corte CMD,
Morikawa N, Fujimoto J, Cristea S, Nguyen T, Diao L, Li L, et al:
Targeting DNA damage response promotes antitumor immunity through
STING-Mediated T-cell activation in small cell lung cancer. Cancer
Discov. 9:646–661. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Jiang M, Chen P, Wang L, Li W, Chen B, Liu
Y, Wang H, Zhao S, Ye L, He Y and Zhou C: cGAS-STING, an important
pathway in cancer immunotherapy. J Hematol Oncol. 13:812020.
View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Pantelidou C, Sonzogni O, De Oliveria
Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J,
Castrillon JA, et al: PARP inhibitor efficacy depends on CD8(+)
T-cell recruitment via intratumoral STING pathway activation in
BRCA-Deficient models of triple-negative breast cancer. Cancer
Discov. 9:722–737. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Ni H, Zhang H, Li L, Huang H, Guo H, Zhang
L, Li C, Xu JX, Nie CP, Li K, et al: T cell-intrinsic STING
signaling promotes regulatory T cell induction and
immunosuppression by upregulating FOXP3 transcription in cervical
cancer. J Immunother Cancer. 10:e0051512022. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Zhang P, Rashidi A, Zhao J, Silvers C,
Wang H, Castro B, Ellingwood A, Han Y, Lopez-Rosas A, Zannikou M,
et al: STING agonist-loaded, CD47/PD-L1-targeting nanoparticles
potentiate antitumor immunity and radiotherapy for glioblastoma.
Nat Commun. 14:16102023. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Lam KC, Araya RE, Huang A, Chen Q, Di
Modica M, Rodrigues RR, Lopès A, Johnson SB, Schwarz B, Bohrnsen E,
et al: Microbiota triggers STING-type I IFN-dependent monocyte
reprogramming of the tumor microenvironment. Cell.
184:5338–5356.e21. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Wu J, Chen YJ, Dobbs N, Sakai T, Liou J,
Miner JJ and Yan N: STING-mediated disruption of calcium
homeostasis chronically activates ER stress and primes T cell
death. J Exp Med. 216:867–883. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Zhang G, Shu Z, Yu J, Li J, Yi P, Wu B,
Deng D, Yan S, Li Y, Ren D, et al: High ANO1 expression is a
prognostic factor and correlated with an immunosuppressive tumor
microenvironment in pancreatic cancer. Front Immunol.
15:13412092024. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Jiang F, Jia K, Chen Y, Ji C, Chong X, Li
Z, Zhao F, Bai Y, Ge S, Gao J, et al: ANO1-mediated inhibition of
cancer ferroptosis confers immunotherapeutic resistance through
recruiting cancer-associated fibroblasts. Adv Sci. 10:e23008812023.
View Article : Google Scholar
|
|
219
|
Kuang L, Pang Y and Fang Q: TMEM101
expression and its impact on immune cell infiltration and prognosis
in hepatocellular carcinoma. Sci Rep. 14:318472024. View Article : Google Scholar
|
|
220
|
Lee Y, Ko D, Yoon J and Kim S:
TMEM52B-derived peptides inhibit generation of soluble E-cadherin
and EGFR activity to suppress colon cancer growth and early
metastasis. J Transl Med. 23:1462025. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Sermeus A, Cosse JP, Crespin M, Mainfroid
V, de Longueville F, Ninane N, Raes M, Remacle J and Michiels C:
Hypoxia induces protection against etoposide-induced apoptosis:
Molecular profiling of changes in gene expression and transcription
factor activity. Mol Cancer. 7:272008. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Berezin IV, Kershengol'ts BM and Ugarova
NN: Microenvironment of enzymes as 1 of the factors determining
enzyme stability. Stabilization of soluble and immobilized
horseradish peroxidase. Dokl Akad Nauk SSSR. 223:1256–1259. 1975.In
Russian. PubMed/NCBI
|
|
223
|
Lee PS, Teaberry VS, Bland AE, Huang Z,
Whitaker RS, Baba T, Fujii S, Secord AA, Berchuck A and Murphy SK:
Elevated MAL expression is accompanied by promoter hypomethylation
and platinum resistance in epithelial ovarian cancer. Int J Cancer.
126:1378–1389. 2010. View Article : Google Scholar
|
|
224
|
Lee H and Evans T: TMEM88 Inhibits Wnt
signaling by promoting Wnt signalosome localization to
multivesicular bodies. iScience. 19:267–280. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Shen DW and Gottesman MM: RAB8 enhances
TMEM205-mediated cisplatin resistance. Pharm Res. 29:643–650. 2012.
View Article : Google Scholar :
|
|
226
|
Shen DW, Ma J, Okabe M, Zhang G, Xia D and
Gottesman MM: Elevated expression of TMEM205, a hypothetical
membrane protein, is associated with cisplatin resistance. J Cell
Physiol. 225:822–828. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Fu Q, Wu X, Lu Z, Chang Y, Jin Q, Jin T
and Zhang M: TMEM205 induces TAM/M2 polarization to promote
cisplatin resistance in gastric cancer. Gastric Cancer.
27:998–1015. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Hu Y, Zhang Y, He J, Rao H, Zhang D, Shen
Z and Zhou C: ANO1: central role and clinical significance in
non-neoplastic and neoplastic diseases. Front Immunol.
16:15703332025. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Vyas A, Duvvuri U and Kiselyov K:
Copper-dependent ATP7B up-regulation drives the resistance of
TMEM16A-overexpressing head-and-neck cancer models to platinum
toxicity. Biochem J. 476:3705–3719. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Carvalho V, Pronk JW and Engel AH:
Characterization of membrane proteins using cryo-electron
microscopy. Curr Protoc Protein Sci. 94:e722018. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Duan J, He XH, Li SJ and Xu HE:
Cryo-electron microscopy for GPCR research and drug discovery in
endocrinology and metabolism. Nat Rev Endocrinol. 20:349–365. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Robertson MJ, Meyerowitz JG and Skiniotis
G: Drug discovery in the era of cryo-electron microscopy. Trends
Biochem Sci. 47:124–135. 2022. View Article : Google Scholar
|
|
233
|
Chang A, Xiang X, Wang J, Lee C, Arakhamia
T, Simjanoska M, Wang C, Carlomagno Y, Zhang G, Dhingra S, et al:
Homotypic fibrillization of TMEM106B across diverse
neurodegenerative diseases. Cell. 185:1346–1355.e15. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Yuan Y, Kong F, Xu H, Zhu A, Yan N and Yan
C: Cryo-EM structure of human glucose transporter GLUT4. Nat
Commun. 13:26712022. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Shang G, Zhang C, Chen ZJ, Bai XC and
Zhang X: Cryo-EM structures of STING reveal its mechanism of
activation by cyclic GMP-AMP. Nature. 567:389–393. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Zhang X, Wu C, Wei T, Lu Y, Liu C and
Zhang J: Cryo-EM studies of the apo states of human IGF1R. Biochem
Biophys Res Commun. 618:148–152. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
García-Nafría J and Tate CG: Cryo-electron
microscopy: Moving beyond X-ray crystal structures for drug
receptors and drug development. Annu Rev Pharmacol Toxicol.
60:51–71. 2020. View Article : Google Scholar
|
|
238
|
Khorn PA, Luginina AP, Pospelov VA,
Dashevsky DE, Khnykin AN, Moiseeva OV, Safronova NA, Belousov AS,
Mishin AV and Borshchevsky VI: Rational design of drugs targeting
G-Protein-coupled receptors: A structural biology perspective.
Biochemistry. 89:747–764. 2024.PubMed/NCBI
|
|
239
|
Madej MG and Ziegler CM: Dawning of a new
era in TRP channel structural biology by cryo-electron microscopy.
Pflugers Arch. 470:213–225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Sung MW, Hu K, Hurlimann LM, Lees JA,
Fennell KF, West MA, Costales C, Rodrigues AD, Zimmermann I, Dawson
RJP, et al: Cyclosporine A sterically inhibits statin transport by
solute carrier OATP1B1. J Biol Chem. 301:1084842025. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Ansell TB, Song W, Coupland CE, Carrique
L, Corey RA, Duncan AL, Cassidy CK, Geurts MMG, Rasmussen T, Ward
AB, et al: LipIDens: Simulation assisted interpretation of lipid
densities in cryo-EM structures of membrane proteins. Nat Commun.
14:77742023. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Ackle F, Thavarasah S, Earp JC and Seeger
MA: Rigid enlargement of sybodies with antibody fragments for
cryo-EM analyses of small membrane proteins. Sci Rep. 15:94602025.
View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Sun C and Gennis RB: Single-particle
cryo-EM studies of transmembrane proteins in SMA copolymer
nanodiscs. Chem Phys Lipids. 221:114–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
